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ABSTRACT
Objective: Histone deacetylases (HDACs) are proteins which play a crucial role in cell growth, maintenance, and regulation. Abnormal HDAC proteins 
produced by genetic mutations are common in human cancers. HDAC10 is a class II HDAC member, and its expression in many cancers has been 
documented. The aim of this study was to determine the best docking of phytocompounds selected from a list of such compounds in the database of 
chemicals for HDAC10.
Methods: The crystal structure of HDAC10 was retrieved from Protein Data Bank and prepared for docking studies by post-translational modification 
(PTM) analysis. Then, we have screened 450 phytocompounds for molecular docking studies and determined their binding affinities against HDAC10 
by using PatchDock server.
Results: The PTM analysis showed that myristoylation sites were more abundant in HDAC10 which might be important functional sites for the gene 
regulation. The results revealed the receptor/inhibitor interactions within an active domain consisting of 30 important amino acid residues. Affinity-
based studies have indicated the docking energy levels by calculating hydrogen bonding, steric, and hydrophobic interactions. Among the inhibitors, 
we could shortlist four compounds which showed excellent binding affinity. Hence, we evaluated drug binding affinities of these four compounds and 
determined their atomic contact energy values. Analysis of the docking results showed holacurtine>periplogenin>3,3’-diindolylmethane>epigallocat
echin as the order of binding affinities, with holacurtine having the best docking score.
Conclusion: It is proposed from these studies that the docking and scoring methods could be useful for selecting and shortlisting the promising 
antitumor molecules. These molecules could be further tested using in vitro and in vivo methods to confirm their role in HDAC10-associated cancers. 
Furthermore, myristoylation sites in HDAC10 could form an important binding site for selecting hit inhibitor compounds. The PTM studies together 
with the binding mode analysis facilitate the protein-protein interaction studies of HDAC10, and thioredoxin-interacting protein is considered as one 
of the transcriptional regulators of HDAC10.
Keywords: Histone deacetylase 10, Post-translational modifications, Phytocompounds, Docking studies, Thioredoxin-interacting protein.
INTRODUCTION
Histones are the basic proteins, and its acetylation process is a key 
prerequisite for chromatin decondensation and structure [1]. Studies 
confirm that histones play a pivotal role in the regulation of chromatin 
structure, function, and dynamics [2,3]. Researches provide the 
information regarding known histone acetyltransferases (HAT) and 
histone deacetylases (HDACs) and their effects on transcription of target 
genes in vivo [4]. HDACs regulate various cellular processes through 
enzymatic deacetylation of both histone and non-histone protein [5]. 
These proteins play crucial roles in a variety of biological processes 
including cell cycle progression, proliferation, differentiation, and 
development [6]. The role of HDAC in cancer was studied for the first time 
in 1998 [7]. Several recent studies also have implicated that individual 
HDAC enzymes can form potential therapeutic targets for treatment 
against cancers, fibrotic disorders, immune and neurological disorders 
[8-10]. HDAC family consists of two major classes, namely class I and 
class II, based on the homologies to yeast deacetylases both share a 
highly conserved catalytic domain which is considered as receptor for 
many drugs, especially in cancer studies [11]. Hence, HDAC inhibitors 
(HDACi) represent a new class of targeted anticancer agents [12].
HDACi has extensively demonstrated the antitumor efficacy in vitro and 
in vivo. In vitro experiments in cancer cell cultures and in vivo studies 
using mouse xenograft model have shown that HDACi delivers potent 
anticancer effects [13]. Therefore, the determination of HDACi has 
become one of the most important research fields of the anticancer 
drugs. Several classes of HDACi have been found to have potential 
anticancer activities and undergoing preclinical studies [14]. Studies 
have reported that HDAC class II proteins were modeled and two 
known inhibitors, namely suberoylanilide hydroxamic acid (SAHA) 
and trichostatin A, were docked using AutoDock to identify the 
pharmacological properties [15]. The inhibition of HDAC activity leads 
to the modulation of expression of a specific set of genes which can 
result in growth arrest, differentiation and apoptosis [16].
HDAC10 is a member of class II HDAC which was first discovered 
based on sequence homology to other class II HDACs and is widely 
expressed in adult human tissues and cultured mammalian cells. It is a 
669 residue polypeptide with a bipartite modular structure consisting 
of an N-terminal Hda1p-related putative deacetylase domain and a 
C-terminal leucine-rich domain [17]. Its mutation leads to various 
cancers [18-20]. Homology comparison indicates that HDAC10 is most 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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similar to HDAC6. Both contain a unique, putative catalytic domain 
which is not found in other HDACs. In HDAC10, however, this domain is 
not functional [21]. HDAC6 is a cytoplasmic deacetylase while HDAC10 
is known to occur in both the nucleus and the cytoplasm. In the nucleus, 
HDAC10 contains a distinct transcriptional repressor domain. It is 
found that HDAC10 might uniquely play roles both in the nucleus, as a 
transcriptional modulator, and in the cytoplasm in an unidentified role 
[21]. It has been found that the knockdown of HDAC10 significantly 
increased the mRNA expression levels of thioredoxin-interacting 
protein (TXNIP) in human gastric cancer cells [22]. Real-time PCR and 
immunoblot analysis confirmed that inhibition of HDAC10 induced 
TXNIP expression, more specifically which is involved in transcriptional 
downregulation of TXNIP. In our previous study, we identified the drug 
binding mechanism of TXNIP [23]. The expression levels of HDAC10 
decrease in lung cancer patients class II HDACs repress critical genes 
and eventually cause the progression of lung cancer [24]. It has been 
found that HDAC10 acts as a promoter of autophagy-mediated survival 
in neuroblastoma cells [25] and chronic lymphocytic leukemia [26].
Only two drug compounds, namely belinostat [27] and 
panobinostat [28], are currently approved as inhibitors for HDAC10. 
This leads to increasing demands for additional therapeutics options 
by administering natural and phytocompounds with lesser side effects. 
Thus, our study is an attempt to determine the binding efficacy of a 
series of phytocompounds and evaluate their interaction with HDAC10. 
To achieve this goal, first, we have used computational algorithms to 
determine the different post-translational modification sites (PTMs) 
and binding sites. Then, docking and its simulation studies were 
performed. We have used several structural algorithms to identify 
binding sites, through analyzing surface structures. In addition, we 
focus mainly on the selection of compounds, and we evaluated the 
binding mode of selected phytocompounds for docking and scoring 
studies. Further, in this study, we also able to understand the drug 
docking mechanism of HDAC10 whether it can give a clue for non-
coding regions and identify conserved sequence elements that may be 
involved in its gene regulation process.
METHODS
HDAC-10 sequence retrieval and its PTMs studies
The query sequence of HDAC10 was retrieved from The UniProt 
Knowledgebase (UniProtKB id: Q969S8). UniProtKB acts as a central hub 
of protein knowledge by providing a unified view of protein sequence 
and functional information [29]. To predict functional sites of HDAC10, 
the query sequence was submitted to Expasy ScanProsite online server 
(https://prosite.expasy.org/scanprosite/) which is a database used 
for structurally conserved motifs scanning included UniProtKB/Swiss-
Prot, splice variants, and UniProtKB/TrEMBL databases. All the default 
settings were considered as parameters for the analysis.
HDAC10 receptor preparation
The receptor structure of HDAC10 was prepared by retrieving the 
three-dimensional crystal structure complex (Protein Data Bank [PDB] 
id:5TD7) bound with a ligand structure, namely 7-[(3-aminopropyl)
amino]-1,1,1-trifluoroheptane-2,2-diol, from RCSB PDB (http://www.
rcsb.org/pdb/home/home.do) [30]. The protein was cleaned by 
removing the bound molecule and the non-essential water molecules. 
Hydrogen atoms were added to the receptor using Biovia DS visualizer 
(Accelrys, BioVia, San Diego, CA, USA).
Binding pocket recognition
The probable ligand binding pockets in HDAC10 were predicted and 
visually identified by MetaPocket server (http://projects.biotec.tu-
dresden.de/metapocket/), which is an online tool that locates and 
measures pockets in the protein structures [31].
Molecules retrieval and ligand preparation
The chemical structures of 450 phytocompounds were known to have 
anticancer activities which were downloaded from NCBI PubChem 
(https://pubchem.ncbi.nlm.nih.gov/) in Standard Data Format (SDF). 
PubChem is an open repository for chemical structures and their 
biological test results [32]. The SDF files were converted to 3D 
structures such as mol2 and PDB using Open Babel [33] converter and 
visualized using Biovia DS visualizer. These molecules were further 
taken for molecular docking studies.
Docking studies using the selected phytocompounds
A geometry-based molecular docking algorithm, namely PatchDock 
server (http://bioinfo3d.cs.tau.ac.il/PatchDock) [34,35], was used for 
docking of HDAC10 with the selected phytocompounds. PatchDock 
is an online docking server which is designed for the purpose of 
the identification of the interaction sites between the receptor and 
ligand molecules. The molecular surface of the protein is divided 
into patches as per the molecular shape followed by the comparison 
between the patches to produce a group of transformations [36]. 
These transformations were further ranked based on the geometric 
complementarity score, and each transformation was assigned to have 
a score, namely PatchDock score and atomic contact energy (ACE) 
values.
Analysis of docking results
To optimize the observed anti-inflammatory and anticancer activities 
from literature studies, we evaluated the binding mode of each docked 
complexes. In this step, the generated poses of each docked complex 
were analyzed and ranked based on their predicted binding energies, 
termed as ACE value. These rankings were used to evaluate the 
binding affinity of the receptor to develop the best conformational fit 
with the ligands selected for analysis. Among the generated multiple 
conformations and associated binding energies, the pose with least 
energy values was considered as the best pose and reported using Biovia 
DS visualizer. The atomic dissolution energy of the derive complex was 
estimated, and the redundant solution was calculated using RMSD, 
clustering during the docking process [34,37]. The docking poses with 
interacting amino acids were graphically represented by Biovia DS 
4.5. The best poses were analyzed for hydrogen bonding, steric, and 
hydrophobic interactions.
Drug-likeness and Lipinski’s rule of five calculation and 
pharmacokinetics evaluation
Molecular descriptors and drug likeliness properties of the selected 
phytocompounds were evaluated using the online tool named as 
Molinspiration server (http://www.molinspiration.com), based on 
Lipinski Rules of five [38]. The smiles format of each of the compound was 
uploaded for the analysis. As per Lipinski’s rule, “drug-like” molecules 
must have log p≤5, molecular weight ≤500, number of hydrogen bond 
acceptors ≤10, and number of hydrogen bond donors ≤5.
RESULTS AND DISCUSSION
PTM analysis of HDAC10
According to prediction results, there were 25 hits for PTMs which 
resulted as three patterns. Protein kinase C phosphorylation, Casein 
kinase II phosphorylation, and N-myristoylation sites were predicted 
as critical biochemical events required for HDAC10 regulation. Three 
regions were identified as protein kinase C phosphorylation sites (amino 
acid residues range from 51 to 53, 345 to 347, and 409 to 411). The 
residues occurring at 417–420 were identified as phosphothreonine, T, 
whereas others were phosphoserine, S. Protein kinase C appeared to 
react with serine or threonine residues that were located at the amino-
terminal (C terminal) side close to lysine or arginine [39]. The results 
showed the low level score for phosphothreonine site as shown in 
Table 1.
Casein kinase II phosphorylation sites were relatively more abundant 
than protein kinase C phosphorylation sites (amino acid residues 
range 51–54, 56–59, 209–212, 309–312, 38–341, 397–400, 417–420, 
and 640–643). N-myristoylation sites were abundant more than other 
functional sites in HDAC10. N-myristoylation sites are involved in the 
amino acids residues ranging from 88 to 93, 120 to 125, 136 to 141,217 
to 222, 219 to 224, 232 to 237, 273 to 278, 294 to 299, 384 to 389, 469 
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to 474,473 to 478,498 to 503, 553 to 558, and 599 to 604. It is found 
that hydrophobic and steric interactions act in concert to anchor to cell 
membranes and proteins that are either myristoylated or farnesylated 
and myristoylation promotes the reversible membrane protein-
protein interactions (PPIs) [40] (Table 2). These results highlight 
N-myristoylation, and Casein kinase II acts as a potential regulator of 
HDAC10 PTM and also shows that regulation of HDAC10 function may 
controlled in part by post-translational phosphorylation.
Protein domain boundaries and the knowledge of its architecture are 
an important aspect for understanding the protein function. Detection 
of protein domain and architecture is a valuable tool in the areas of 
protein science, protein structure prediction, etc., [41]. These setups 
allowed us to study the behavior of residues and its role in PTMs and 
motif functionality. PTM studies provide an extensible clue about 
protein’s regulation process [42]. These features include the nature 
of signal transduction, protein stability, etc. [43]. The mechanism of 
transcriptional regulation of HDAC10 with respect to drug binding 
with phytocompounds remains poorly understood. Therefore, multiple 
strategies, including motif and domain, were determined to recognize 
binding sites to further study the docking and its dynamics. Thus, 
we hypothesize that a more reliable mechanism is highly desirable 
to determine the binding sites, binding mode, and its role in various 
cancers.
Binding site determination
Eight important binding pockets were determined as catalytic sites of 
the HDAC-10 receptor using metaPocket server. After clustering, the 
top three sites from the base methods, namely PASS11 (PAS), LigsiteCS 
(LCS), Q SiteFinder (QSF), GHECOM (GHE), POCASA (PCS), Fpocket 
(FPK), SURFNET (SFN) and ConCavity (CON), were the base methods 
incorporated to predict all the top eight clusters. MetaPocket running 
report is shown in Table 3. The first MetaPocket site consists of five 
pocket sites with total Z score of 19.45 from SFN-1’, “LCS-1,” “FPK-1,” 
“CON-2,” and “GHE-2.” The second MetaPocket site consists of 6 pocket 
sites with a total Z score of 17.42 from GHE-1’, “FPK-2,” “LCS-2,” “SFN-
2,” “PAS-2,” and “CON-1,” and the third MetaPocket site consists of 1 
pocket site with a total Z score of 2.51 from SFN-3. Eight header binding 
sites with potential binding site residues of the receptor are shown 
in Table 4. The identification of binding sites is an important step in 
structure-based drug design, as this helps to understand the functional 
sites and its mechanism of action of the protein [44]. These identified 
active sites were helpful to evaluate further the binding mode of docked 
complexes. Thus, we focused on the binding mode of the residues and 
evaluated its affinity to the HDAC10 receptor during the selected drug-
interaction studies through docking.
HDAC10 and phytocompound binding mode analysis
To analyze the reliability of interaction mode between HDAC10 and 
the compounds, namely periplogenin 3,3’-diindolylmethane and 
epigallocatechin, the binding energy score values were determined. 
Molecular docking is the standard method used to determine the 
binding mode of molecules with the receptors; docking was used [45,46] 
in many studies. In our study, holacurtine showed a lesser energy 
value of −300.21 compared to other three compounds. The predicted 
interacting residues obtained by drug interaction studies were matched 
with the predicted binding pocket amino acids of MetaPocket server.
Holacurtine formed hydrogen bonds with Leu362, Ala363, Gln364, and 
Arg658 and steric interactions with Ser358, His361, Leu362, Ala363, 
Gln364, Val651, and Arg658. Holacurtine is only involving in the 
formation of hydrogen bond and hydrophobic bonds. Holacurtine does 
not form any hydrophobic bonds. In addition, inter-residue hydrogen 
bond interaction (Arg658-Glu655, Arg658-Met654, Arg658-Cys670, 
Glu652-Glu655, Glu655-Val651, and His361-Leu362) are involved in 
anchoring the holacurtine to the receptor HDAC10 (Fig. 1). Periplogenin 
forms hydrogen bond with Gln659, steric interactions with Arg658, 
Glu655, and Glu674, and hydrophobic interactions with His361. Arg658-
Cys670, Arg658-Glu655, Arg658-Leu668, Gln659-Glu655, and Glu674-
Trp676 forms inter-residue interactions with periplogenin as shown 
in Fig. 2. 3,3’-Diindolylmethane forms hydrogen bond interaction with 
Glu655, steric interactions with Arg349, Thr671, Arg658, and Glu655, 
and one hydrophobic bond with Cys670. Glu655-Val651, Arg349-
His246, Arg658-Cys670, Arg349-Phe359, Arg658-Glu655, Arg658-
Met654, and Cys670-His246 form inter-residue interactions with 
3,3’-Diindolylmethane (Fig. 3). Epigallocatechin forms hydrogen bonds 
with Arg349, Arg658, Glu655, Arg349, and Gly567, steric interactions 
Table 1: Post-translational modifications (phosphorylation sites) of HDAC10
S.no Site Definition Region Modified residue
Serine (S) Threonine (T)
1. PS00005 PKC_PHOSPHO_SITE, Protein kinase 
C phosphorylation site
51–53; 345–347; 409–411 51; 345; 409
2. PS00006 CK2_PHOSPHO_SITE, casein kinase 
II phosphorylation site
51–54; 56–59; 209–212; 
309–312; 338–341; 397– 400; 
417–420; 640–643; 
51; 56; 209; 309; 338; 397; 640 417
HDAC10: Histone deacetylase 10
Table 2: Post-translational modifications (myristoylation sites) 
of HDAC10















HDAC10: Histone deacetylase 10
Table 3: Predicted ligand binding clusters site of receptor, 
HDAC10, using MetaPocket server
Clusters Z score Number of 
pocket sites
Methods
1. 19.45 5 “SFN-1,” “LCS-1,” “FPK-1,” 
“CON-2,” “GHE-2”
2. 17.42 6 “GHE-1,” “FPK-2,” “LCS-2,” 
“SFN-2,” “PAS-2,” “CON-1”
3. 2.51 1 “SFN-3”
4. 1.78 1 “PAS-1”
5. 0.99 1 “LCS-3”
6. 0.47 1 “PAS-3”
7. 0.44 1 “GHE-3”
8. −0.69 2 “FPK-3,” “CON-3”
HDAC10: Histone deacetylase 10
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with Lys360 and Arg658, and hydrophobic interactions with His361. 
Arg349-His246, Arg349-Phe359, Arg658-Cys670, Arg658-Glu655, 
Arg658-Met654, Arg658-Lue568, Gly567-Gln563, and His361-Leu362 
form inter-residue interactions with Epigallocatechin (Fig. 4).
Arg658 was found to be one of the critical amino acid residues which 
occurs in all the four molecules which form hydrogen bond and steric 
interactions in holacurtine and epigallocatechin and steric interactions 
in all the four compounds. Periplogenin, 3,3’-diindolylmethane, and 
epigallocatechin showed similar degree of hydrophobic residues (one 
residue each) that take part in hydrophobic interaction. Periplogenin 
and epigallocatechin have a consensus hydrophobic interaction residue 
His361; also the same residue His361 forms a steric interaction with 
holacurtine (Table 5). 
Hydrophobic residues are critical determinants of ion selectivity. With more 
the hydrophobic residues, more will be the affinity and the overall effect will 
be greater for alkyl substituents. Studies suggest that ion selectivity mainly 
involves in cysteine residues [47]. Intermolecular binding shows the measure 
of binding stability between a protein and its binding components [48]. The 
Table 4: Predicted ligand binding site residues in the receptor, HDAC10 using MetaPocket server
Binding site Residues
Header binding site 1 LEU_A^362^, VAL_A^651^, GLU_A^652^, GLU_A^655^, LYS_A^360^, HIS_A^361^, LYS_A^656^, PRO_A^648^, GLN_
A^364^, GLN_A^659^, SER_A^358^, ARG_A^349^, MET_A^654^, ARG_A^658^, PHE_A^359^, CYS_A^670^, SER_A^357^, 
THR_A^671^, ALA_A^363^, LEU_A^568^, GLN_A^563^, PRO_A^646^, GLN_A^662^, GLN_A^346^, ALA_A^645^, GLY_
A^567^, ARG_A^669^, VAL_A^672^, GLU_A^674^, ASN_A^350^, PRO_A^250^, HIS_A^246^, PHE_A^245^, LEU_A^566^, 
GLU_A^663^, TRP_A^676^, GLU_A^649^, LYS_A^647^, ALA_A^559^, GLY_A^560^, ASP_A^650^, LEU_A^551^, ALA_
A^564^, MET_A^653^, ARG_A^644^, ASN_A^347^, GLU_A^254^, SER_A^353^, SER_A^673^, SER_A^675^
Header binding site 2 PRO_A^428^, SER_A^630^, ALA_A^635^, ALA_A^296^, SER_A^636^, ARG_A^122^, SER_A^633^, MET_A^292^, PRO_
A^293^, CYS_A^603^, ILE_A^637^, GLY_A^634^, LYS_A^298^, ALA_A^1^, ALA_A^2^, HIS_A^289^, ARG_A^414^, GLN_
A^606^, ALA_A^631^, GLY_A^297^, ARG_A^125^, ASN_A^430^, LYS_A^429^, LEU_A^294^, VAL_A^119^, THR_A^328^, 
GLY_A^611^, ASN_A^483^, ARG_A^610^, ASN_A^126^, VAL_A^124^, SER_A^3^, GLY_A^607^, PRO_A^327^, LEU_A^608^, 
GLY_A^325^, SER_A^322^, CYS_A^431^, ASP_A^326^, CYS_A^482^, MET_A^299^, LEU_A^323^, LEU_A^324^, GLY_A^4^, 
SER_A^412^, VAL_A^413^, GLU_A^480^, ARG_A^48^, SER_A^5^, ASP_A^479^, VAL_A^260^, LEU_A^291^, ALA_A^295^, 
SER_A^638^
Header binding site3 ILE_A^437^, VAL_A^445^, LEU_A^462^, ARG_A^463^, SER_A^464^, LEU_A^465^, GLY_A^466^
Header binding site 4 ASP_A^22^, TYR_A^92^, ASP_A^94^
Header binding site 5 PRO_A^420^, PRO_A^421^, VAL_A^487^, SER_A^489^, ASN_A^460^, ILE_A^461^, SER_A^464^, VAL_A^488^, PRO_
A^419^, ARG_A^463^, ASN_A^467^, VAL_A^418^, VAL_A^486^, SER_A^434^, HIS_A^433^, ILE_A^437^
Header binding site 6 GLU_A^540^, ARG_A^552^, MET_A^653^ 
Header binding site 7 GLY_A^518^, LYS_A^537^, THR_A^539^, GLU_A^519^, ASP_A^517^, GLU_A^538^, CYS_A^535^, GLN_A^533^, THR_
A^536^, THR_A^548^, LEU_A^520^, GLU_A^540^, ASP_A^541^, ARG_A^546^, LYS_A^542^ LYS_A^523^, VAL_A^522^, 
PRO_A^521^, CYS_A^543^, THR_A^524^, LEU_A^531^, VAL_A^544^, ASN_A^545^
Header binding site 8 PRO_A^23^, ALA_A^24^, ASP_A^94^, GLU_A^274^, ILE_A^27^, PHE_A^146^, HIS_A^176^, PHE_A^307^, PRO_A^134^, 
GLY_A^135^, HIS_A^136^, HIS_A^137^, CYS_A^147^, ASP_A^174^, GLU_A^304^, GLY_A^305^, GLY_A^145^, ASP_A^267^, 
TRP_A^205^, PRO_A^273^, ASP_A^272^, GLU_A^28^, ARG_A^32^, CYS_A^25^
Fig. 1: Docking of holacurtine with histone deacetylase10 
receptor showing interactions
Fig. 2: Docking of periplogenin with histone deacetylase10 
receptor showing interactions
Fig. 3: Docking of 3,3’-diindolylmethane with histone deacetylase 
10 receptor showing interactions
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predicted residue contacts information that will be able to predict interacting 
helical pairs and helix-helix interactions and predict residue contacts. 
Inter-residue atomic interactions including hydrogen bonds, hydrophobic 
interactions, salt bridges, and electrostatic (steric) interactions were 
computed between pairs of amino acid residues within the HDAC10 receptor. 
Since amino acid interactions are important determinants of protein fold-
function-evolution relationships [49], folding initiation sites contain not only 
accepted “hydrophobic” amino acids but also larger charged side chains [50].
Conservation of inter-residue interactions will be helpful to predict the 
folding rate of domain and repeats in proteins [51]. It has been found 
that, during the process of protein folding, the amino acid residues 
along the polypeptide chain interact with each other to form the stable 
native structure. The knowledge about inter-residue interactions in 
protein structures helped us to understand the mechanism of protein 
folding and stability [52]. From the above results of interaction 
energy and residues forming H-bonds, hydrophobic interactions, 
and inter-residue interaction, four compounds were ranked in the 
order with respect to the predicted effectiveness of binding such as 
Holacurtine>Periplogenin>3,3’-diindolylmethane>epigallocatechin. 
Subsequently, ‘Lipinski’s rule of five’ was performed to check the oral 
bioavailability of the molecules. Those molecules which do not satisfy 
one or more of Lipinski’s rules were predicted to have issues with 
oral bioavailability. Molinspiration calculated all important molecular 
properties such as LogP, polar surface area, number of hydrogen bond 
donors and acceptors as presented in Table 6. TPSA (topological polar 
surface area) or PSA (polar surface area) is the term to describe the 
surface sum of all polar atoms, primarily oxygen and nitrogen, and 
attached hydrogens, generally  PSA is used to calculate the percentage 
of absorption [53]. PSA is also considered as a suitable descriptor 
which determines H-bonding potential of drugs. For the molecules to 
penetrate the blood brain barrier, PSA value of less than 90 angstroms 
is preferred [54]. Taken together, our results demonstrated that binding 
site residues of HDAC10 may have undergone specific types of changes 
to develop various interactions that influence ligand anchorage and 
thus receptor-binding affinity of HDAC10. This study emphasizes that 
docking is one of the valuable methods to determine the receptor-drug 
interactions and to assess the affinity toward the receptor structures 
(Table 6).
Phytocompounds are known to possess anti-inflammatory and antitumor 
activities which are involved in tumor growth and metastasis [55,56] 
and also act as potential antibacterial components [57]. Although there 
exist various evidences and links between the phytocompounds and 
its interaction between HDACs [58-60], identification of binding sites 
and their binding mode is an important factor for each class of HDACs. 
It is mandatory to evaluate the specificity, drug-like characteristics, 
and pharmacokinetic profile of phytocompounds [61]. Major goal 
of structural biology deals with the formation of protein-ligand 
complexes. It has been demonstrated that an alkaloid, namely VI, was 
screened against various cancer cell lines and showed significant 
anticancer activity with IC50 value in the range of 0.89–1.40 μM [62]. 
The role of receptor-ligand interaction helps to study the conceptual 
biology of protein function through docking analysis. Perceptive 
protein-ligand interactions will, therefore, be very important in drug 
discovery research. In this scenario, docking aids in identifying the 
transformation of one molecule to which other molecules can fit in 
devoid of any steric changes. This molecular docking study revealed 
the critical residues that take part in the HDAC10 binding mechanism. 
Our investigation revealed the overall accuracy and coverage values for 
drug binding mechanism of selected phytocompounds against HDAC10.
CONCLUSION
Our study demonstrated for the first time that, using the computational 
analysis, we could select four phytocompounds from the list of 450 
phytocompounds. The selected compounds showed excellent binding 
interactions specifically for HDAC10. By employing docking and 
scoring analyses, we studied the binding mode of these four molecules 
and found that holacurtine, periplogenin, 3,3’-diindolylmethane, and 
epigallocatechin could potentially interact with HDAC10 in that order. 
These results provided valuable information about the essential 
structural features of effective HDAC10 inhibitors. These molecules 
Table 5: Docking of the four compounds based on the docking score and interaction of residues










1. Holacurtine (10390928) Leu362, Ala363, Gln364, 
Arg658, 
Ser358, His361, Leu362, Ala363, 
Gln364, Val651, Arg658
- 6560 −300.21
2. Periplogenin (10574) Gln659 Arg 658, Glu655, Glu674 His361 4944 −16.72
3. 3,3’-diindolylmethane (3071) Glu655 Arg349, Thr671, Arg658, Glu655 Cys670 4676 −102.21
4. Epigallocatechin (72277) Arg349, Arg658, Glu655, 
Arg349, Gly567
Lys360, Arg658 His361 4220 −136.75
ACE: Atomic contact energy
Table 6: Drug likeness score for the four phytocompounds
Molecule (PubChem compound id) miLogP TPSA MW N atoms nON nOHNH nrotb N violations Volume
Holacurtine (10390928) 4.04 77.03 491.71 35 6 2 5 0 493.13
Periplogenin (10574) 1.53 86.99 390.52 28 5 3 1 0 372.33
3,3’-Diindolylmethane (3071) 4.20 31.58 246.31 19 2 2 2 0 230
Epigallocatechin (72277) 1.08 130.60 306.27 22 7 6 1 0 252.16
Fig. 4: Docking of epigallocatechin with histone deacetylase10 
receptor showing interactions
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could be validated to check its ADME, IC50 value, and anti-inflammatory 
responses using both in vitro and in vivo methods. The computational 
observations of PTM together with the binding mode information have 
given information in the field of SNP and mutation studies as well as 
paved the way for new research approach for efficiently selecting 
critical regions and sites including non-coding residues for drug binding 
domains which may have great scope in cancer research. Furthermore, 
the PTM studies could form a starting point to further understand its 
PPI with TXNIP protein and regulation mechanisms which is still not 
yet determined. The docking and dynamics score studies demonstrated 
the selection procedure of phytocompounds toward the receptor, and 
these methodologies might be helpful for developing new drugs for 
HDAC10 protein driven cancers.
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